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Carbohydrate-binding agents (CBAs) have been proposed as innovative anti-HIV compounds selectively targeting the glycans of the HIV-1
envelope glycoprotein gp120 and preventing DC-SIGN-directed HIV capture by dendritic cells (DCs) and transmission to CD4+ T-lymphocytes. We
now show that CBAs efficiently prevent R5HIV-1 infection of human primary monocyte-derived macrophage (MDM) cell cultures in the nanomolar
range. Both R5 and X4 HIV-1 strains were efficiently captured by the macrophage mannose-binding receptor (MMR) present on MDM. HIV-1
capture by MMR-expressing MDMwas inhibited by soluble mannose-binding lectin and MMR antibody. Short pre-exposure of these HIV-1 strains
to CBAs is able to prevent virus capture by MDM and subsequent syncytia formation in cocultures of the CBA-exposed HIV-1-captured MDM and
uninfected CD4+ T-lymphocytes. The potential of CBAs to impair MDM in their capacity to capture and to transmit HIV to T-lymphocytes might be
an important property to be taken into consideration in the eventual choice to select microbicide candidate drugs for clinical investigation.
© 2007 Elsevier Inc. All rights reserved.Keywords: Monocyte-derived macrophages (MDMs); Carbohydrate-binding agents (CBAs); Glycans; HIV-1; Envelope glycoprotein gp120; HIV-1 capture;
HIV-1 transmission; DC-SIGN; Macrophage mannose-binding receptor (MMR)Introduction
Antigen-presenting cells (APCs) [primary monocyte-derived
macrophages (MDMs) and dendritic cells (DCs)] are a major
target/reservoir for viral infection, and play an important role in
activating the immune system. They process and present antigens
for stimulation of primary and secondary T-cell responses in
various forms byMHC class I and II pathways (Banchereau et al.,
2001; Chougnet et al., 2002).MDMandDC are known to express
the CD4 receptor and are susceptible to infection with human⁎ Corresponding author.
E-mail address: jan.balzarini@rega.kuleuven.be (J. Balzarini).
1 Thisworkwas performed during a postdoctoral fellowship at theRega Institute.
0042-6822/$ - see front matter © 2007 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2007.08.033immunodeficiency virus type 1 (HIV-1). MDM and DC may be
the first cells in the subepithelial vaginal mucosa to be bound by,
or infected with, HIV-1 during heterosexual transmission
(Greenhead et al., 2000; Hu et al., 2000). They are believed to
act as reservoirs for virus replication and dissemination in all body
compartments by their migratory capacity (Cameron et al., 1996).
While HIV-1 infection is associated with abnormalities in most
compartments of the immune system, defects in cell-mediated
immunity appear to be of clinical importance. Impaired APC
function is thought to be a critical component of HIV-1-associated
immunodeficiency (Chougnet, 2003; Donaghy et al., 2004).
Whereas immature DC are characterized by the presence of the
C-type lectin DC-SIGN (dendritic cell-specific ICAM-3 grabbing
non-integrin) (Geijtenbeek et al., 2000), MDM express another
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ptor (MMR). The MMR is a 175-kDa transmembrane glyco-
protein containing three distinct domains, two of which have
carbohydrate-recognizing properties. The C-type lectin do-
mains facilitate carbohydrate-dependent uptake of mannosy-
lated protein antigens present on microorganisms including
bacteria, yeast, enveloped viruses and protozoans (Reading
et al., 2000). The MMR shows high affinity for mannose and
fucose, intermediate affinity for N-acetylglucosamine (GlcNAc)
and glucose and low affinity for galactose (Stahl and Ezekowitz,
1998). Because these terminal sugars are rarely found on the
mammalian cell-surface, the MMR could be responsible for dis-
crimination between self and non-self antigens (Engering et al.,
1997). It also plays a key role in pathogen-related acquired host
defence by mediating antigen internalization and delivery to
MHC class II compartments for antigen presentation (Engering
et al., 1997; Tan et al., 1997). Thus it is clear that both DC-SIGN
on immature dendritic cells, and MMR on MDM can capture
pathogens such as HIV, and present them to T-lymphocytes for
further provoking a specific immune response. MDM contribute
to the transmission and the pathogenesis of HIV-1 infection
throughout the progression of HIV-1 infection especially at lateFig. 1. Inhibitory activity of test compounds against R5 HIV-1 (Ba-L) infection of MD
to infection with HIV-1 (Ba-L) for 2 h. After several washing steps of the MDM cul
was quantified by p24 ELISA at day 14 after the infection.stages of disease characterized by extensively depleted CD4+
T-lymphocyte pools (Badley et al., 1997; Herbein et al., 2002;
Tomkowicz et al., 2006; Williams and Hickey, 2002).
HIV-1 is an enveloped virus whose heavily glycosylated
surface glycoprotein gp120 binds CD4 and a co-receptor of the
target cell to initiate infection. A significant proportion of the
gp120 glycosylation sites are highly (terminally) mannosylated, a
pattern common to several other pathogens (Nguyen andHildreth,
2003; Balzarini, 2007b). Carbohydrate-binding agents (CBA)
have been recently proposed as innovative anti-HIV compounds
selectively targeting the glycans of the HIV-1 envelope glyco-
protein gp120 (Balzarini, 2005). Short pre-exposure of HIV-1 to
CBAs prevents DC-SIGN to efficiently bind HIV-1 and prevent
subsequent syncytia formation upon cocultivation of DC-expres-
sing cells with T-lymphocytes (Balzarini et al., 2007a). Indeed, the
mannose-specific CBAs (i.e. the plant lectins HHA, GNA, NPA
and CA; the procaryotic cyanovirin-N (CV-N)) and the GlcNAc-
specific plant lectin UDA but not other entry inhibitors, nor poly-
anionic compounds, efficiently abrogate the DC-SIGN-directed
HIV-1 capture and subsequent transmission to T-lymphocytes.
Such compounds should have the potential to impair the ability of
DC to capture HIV and to transmit the virus to T lymphocytesM.MDMwere exposed to various dilutions of the test compounds (30 min) prior
tures, new medium containing test compounds was added. The virus production
Fig. 2. Capture of various HIV-1 strains by Raji/DC-SIGN cells and MDM in
presence or in absence of CBAs. (A) Raji/DC-SIGN and MDMwere exposed to
several strains of HIV-1. After the time of infection, the cells were washed to be
sure to remove the unbound virus. The Raji/DC-SIGN cell cultures and MDM
were then analysed for p24 content by a p24 ELISA. (B) HIV-1 (NL4.3)
particles were exposed to various dilutions of the test compounds (30 min) prior
to administration to MDM for 2 h. After removal of unbound virus by several
washing steps, cell-associated virus was qualified by p24 ELISA.
Table 1
Inhibitory activity of CBAs against HIV-1(BaL) infection of MDM and HIV-1
(IIIB) infection of C8166 lymphocytes
CBA HIV-1(BaL) in MDM HIV-1(IIIB) in
T-lymphocytes
EC50
a (μM) EC90
b (μM) MIC c (μM) EC50
d (μM)
HHA 0.040 0.132 N2 0.260
GNA 0.038 0.666 N2 0.400
NPA 0.026 0.174 N2 0.018
CA 0.01 0.10 N4 0.036
UDA 0.207 0.415 N10 2.8
CV-N 0.0005 0.002 N0.35 0.0006
PRM-A 3.8 9.5 N60 4.8
T20 (enfuvirtide) 0.02 – – 0.16
a 50% Effective concentration or compound concentration required to inhibit
HIV-1(BaL) p24 production in virus-infected monocyte-derived macrophages
by 50% at day 14 post infection.
b 90% Effective concentration or compound concentration required to inhibit
HIV-1(BaL) p24 production in virus-infected monocyte-derived macrophages
by 90% at day 14 post infection.
c Minimal inhibitory concentration or compound concentration required to
afford microscopically visible alteration of cell morphology upon visual
inspection and trypan blue dye staining.
d 50% Effective concentration or compound concentration required to inhibit
HIV-1(IIIB)-induced cytopathicity in T-lymphocyte C8166 cell cultures at day 3
post infection (data taken from Balzarini et al., 2007a,b).
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entry inhibitors (i.e. the gp41 inhibitor enfuvirtide and the CXCR4
and CCR5 antagonists) that inhibit the transmission of the virus to
T-cells in cocultivation assays of persistently HIV-1-infected cells
and uninfected cells, but not the transmission of the virus through
DC-SIGN-expressing cells (Balzarini, 2007a). The aim of this
study was to investigate the ability of CBAs to inhibit HIV-1
capture by MDM, one of the major cellular targets for HIV-1
infection and prominent virus reservoir, and to inhibit the
subsequent virus transmission from HIV-1-captured MDM to
CD4+ T-lymphocytes. Our data show that efficient HIV-1 capture
occur byMDMs, which lack measurable expression of DC-SIGN
but abundantly express theMMR.CBAs efficiently block theHIV
capture by MDM and subsequent virus transmission to T-
lymphocytes, a property that is beneficial from a microbicidal
viewpoint.
Results
Antiviral activity of CBAs in HIV-1/BaL-infected MDM
MDM shortly (30 min) pre-incubated with several concentra-
tions of CBAs were infected with HIV-1 BaL (3000 pg/ml) and
supernatants were collected at days 7 and 14. The HIV-1 p24
ELISA analysis at day 14 revealed that CBAs are able to ef-
ficiently prevent HIV-1 BaL replication in MDM in a dose-
dependent fashion. Results are expressed as the percentage of the
p24 values of the untreated controls, inwhichMDMwere exposed
to HIV-1 BaL in the absence of the CBAs (Fig. 1). The EC50 (μM)
and EC90 (μM) values were shown in Table 1. The geometric
mean of p24 gag production was used to determine the effective
drug concentration where 50% and 90% of viral replication isinhibited. A linear regression of the log percent HIV-1-p24 prod-
uction (compared to untreated controls) versus the log of the drug
concentration was plotted to calculate the EC50 and EC90 values.
The mannose-specific plant lectin-derived HHA, GNA, CA and
NPA, and the GlcNAc-specific UDAwere markedly effective in
inhibitingHIV-1BaLp24 production inMDM (EC50 values in the
nanomolar range). The procaryotic mannose-specific cyanovirin-
N (CV-N) proved exquisitely inhibitory toHIV-1/BaL infection of
MDM (EC50 in the higher picomolar range). The non-peptidic
antibiotic PRM-A was inhibitory in the lower micromolar range
and less effective than the plant lectin CBAs. In most cases, the
inhibitory values in MDM were within the same order of
magnitude as in T-lymphocytes (Table 1). The CBAs were not
toxic to the MDM cultures at concentrations that were markedly
higher than the antivirally effective concentrations (2 μM for
HHA, GNA and NPA; 4 μM for CA; 10 μM for UDA; 60 μM for
PRM-A; and 0.36 μM for CV-N).
Capture of various HIV-1 strains by B-lymphocyte
Raji/DC-SIGN cells and MDM
Exponentially growing Raji/DC-SIGN cells and MDM
were exposed to a variety of HIV-1 strains for 1 or 2 h,
respectively. Then, the unadsorbed virus was carefully
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p24, attached to the cells, determined by HIV-1 p24 ELISA. It
should be mentioned that it would be unlikely that any HIV-1
(p24) was internalized into the Raji cells, since HIV-1-exposed
control cultures of wild-type Raji/0 cells were p24-negative,
and no evidence of productive virus infection of Raji/DC-
SIGN was observed.
The results depicted in Fig. 2A represent the percentage of
capturedHIV-1 p24 compared with the initial input of HIV-1 p24
to the MDM. HIV-1 p24 associated with Raji/DC-SIGN cells
and MDM could be reliably measured. HIV-1 NL4.3 was most
efficiently captured (to the amount of ∼10% of input virus),
whereas HIV-1 IIIB was the least efficiently captured (∼1% of
input virus). When Raji/DC-SIGN and MDM were compared,
for each individual virus strain, highly similar capture effi-
ciencies were observed for DC-SIGN-expressing cells and
MDM irrespective whether the virus represented an X4 or R5
isolate (correlation coefficient: r=0.9) (Fig. 2A). Since the
different stocks of the X4 HIV-1 strains were originally preparedFig. 3. Effect of test compounds on the transmission of HIV-1 particles byMDM to C8
HIV-1 (NL4.3)-exposed MDM (the unadsorbed virus to the MDM was carefully rem
uninfected C8166 cells). (B) Microscopic view of a 3-day coculture of uninfected C8
dilutions of the test compounds (prior to administration to MDM for 2 h (C: UDA; D
cocultivated with C8166 cells. The virus production was quantified by p24 ELISA ain similar MT-4 cell cultures, we believe that differences in virus
capture reflect differences in envelope glycans and structure,
rather than differences in how the virions were prepared.
Inhibitory effect of CBAs on the ability of MDM to capture
HIV-1 particles
To investigate whether CBAs may be useful as potential
microbicide drugs, HIV-1 NL4.3 particles (100 μl;
67×103 pg/100 μl) were exposed to serial dilutions of the
test compounds for 30 min. Then, the drug-exposed virus
suspensions were added to MDM for 2 h at 37 °C after which
the cells were thoroughly washed with 1 ml RPMI-1640 (20%
FBS) as described above. MDM were detached and then
analyzed for p24 content by ELISA. The HIV-1 p24 content
from the last wash supernatant was below detection limit. This
revealed that unadsorbed virus particles in the medium were
absent and that the HIV-1 p24 values solely represent virus
amounts captured by the MDM. Data are expressed as a166 cells. (A) Microscopic view of a 3-day coculture of uninfected C8166 cells+
oved after a 30-min incubation time prior to cocultivation of the MDM with the
166 cells+MDM. HIV-1 (NL4.3) particles were exposed for 30 min to various
: NPA). After removal of unbound virus by several washing steps MDM were
fter 3 and 4 days of coculture.
386 M. Pollicita et al. / Virology 370 (2008) 382–391percent of the p24 value of MDM control cultures that were
incubated with HIV-1 NL4.3 in the absence of the CBAs.
The results show that the CBAs dose-dependently inhibited
capture of HIV-1 NL4.3 by the MDM (Fig. 2B). The mannose-
specific NPA inhibited virus capture at an IC50 of ∼0.4 μM
whereas the IC50 of the GlcNAc-specific UDA was ∼60 μM.
The mannose-specific non-peptidic antibiotic PRM-A was also
inhibitory to HIV-1 NL4.3 capture by MDM, albeit at a much
higher drug concentration (Fig. 2B).Fig. 4. Effect of antibodies against the macrophage mannose receptor, DC-SIGN and
10 μg/ml MMR antibody, DC-SIGN antibody or CD4 antibody for 15 min at 37 °C, a
detached for HIV-1 p24 capture analysis (A). For the transmission experiments, C816
HIV-1 p24was done at days 3 and 4 after coculturingMDMwith C8166 cells (B). (C)M
exposedMDM (the unadsorbed virus in theMDM cultures was carefully removed afte
C8166 cells). (D, E, F) 3-day coculture of uninfected C8166 cells+HIV-1 exposed MDInhibitory effect of CBAs on the ability of MDM to transmit
captured HIV-1 particles
BecauseMDMcan capture HIV-1 particles and transmit HIV-
1 to T-cells we wanted to investigate whether CBAs are able to
prevent the transmission of the CBA-exposed virus particles
from MDM to cocultured C8166 T-lymphocytes. As described
for the virus capture, 67×103 pg of HIV-1 were exposed to serial
dilutions of the test compounds for 30 min. CBA-exposed virusCD4 on HIV-1 capture and transmission by MDM. MDM were incubated with
fter which HIV NL4.3 was added. After 2 h, MDMwere thoroughly washed and
6 cells were added to antibody-treated HIV-1-exposed MDM and the analysis of
icroscopic view of a 3-day cocultures of uninfected C8166 cells+HIV-1 NL4.3-
r a 30-min incubation time prior to cocultivation of theMDMwith the uninfected
M pre-treated with specific CD4, DC-SIGN and MMR antibodies, respectively.
Fig. 5. Inhibitory effect of mannan on the ability of MDM to capture HIV-1.
Mannan (2.5 mg/ml) was added to the MDM cultures by two different
procedures: (i) the mannan was added to MDM for 15 min at 37 °C and then the
virus was added; (ii) the mannan was mixed with the virus and then the mannan/
virus mixture was exposed toMDM. After 2 h, MDMwere washed and analysed
for the captured p24.
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cells were thoroughly washed to remove excess of CBA and
unbound virus. Then C8166 cells were added to the MDM
cultures and cocultivated for 3 additional days. In a coculture of
uninfected C8166 cells with HIV-1 NL4.3-exposed MDM,
abundant giant cell formation and virus production is observed at
day 3 after initiation of the cocultivation (Fig. 3A). On the
contrary, no syncytia weremicroscopically observed to appear in
the C8166 coculture with uninfected MDM (Fig. 3B). Inter-
estingly, uninfected C8166 cells were predominantly clustered at
the site of MDM locations in the cultures. The percentage of
HIV-1 transmission was expressed as the percent of the p24
value of the positive control, in which MDM were exposed to
HIV-1 NL4.3 that were not treated with CBAs. In the control
cocultures (HIV-1-exposed MDM+C8166), significant
amounts of HIV-1 p24 were produced. As shown in Fig. 3,
both UDA (C) and NPA (D) were able to markedly and dose-
dependently prevent the transmission of CBA-exposed HIV-1
from MDM to T-lymphocytes.
DC-SIGN and MMR expression in MDM cultures
We have examined the expression of DC-SIGN and MMR in
MDM by flow cytometric analysis. MDM were stained with
DC-SIGN and MMR antibodies and analyzed on a Becton
Dickinson FACScan flow cytometer using CellQuest software.
Flow cytometric analysis revealed that the MDM expressed
MMR on their membrane (∼12% positive), whereas very little,
if any expression of DC-SIGN (b1% positive) was observed.
This indicates that the latter C-type lectin receptor does not
significantly contribute to the HIV-1 binding to MDM.
Role of the macrophage mannose receptor, DC-SIGN and CD4
on HIV-1 capture and subsequent transmission by MDM
To study the role of MMR in the capture and transmission of
HIV-1, the effect of an anti-MMR antibody was compared with
antibodies directed against several other receptors. MDM were
incubated with anti-MMR antibody (10 μg/ml), anti-DC-SIGN
antibody (10 μg/ml), and anti-CD4 antibody (10 μg/ml), for
15min at 37 °C. HIVNL4.3 (67×103 pg/100 μl) was then added
to theMDMand exposed for 2 h at 37 °C. Cells were washed and
detached for HIV-1 p24 capture analysis (Fig. 4A). For the
transmission experiments, C8166 cells were added to antibody-
treated MDM and the analysis of HIV-1 p24 was determined at
day 3 after coculturing HIV-1-exposed MDM with C8166 cells
(Fig. 4B). The percentage of captured and transmitted HIV-1was
expressed as a percentage of the value of the positive control, in
which MDM were incubated without CBAs.
The MMR antibody proved able to prevent both HIV-1
particle capture by MDM and subsequent virus transmission to
C8166, while CD4 and DC-SIGN antibodies do not prevent
these events. These observations show the importance of MMR
but not DC-SIGN or CD4 in the capture and the transmission of
HIV-1 particles from MDM to T-lymphocyte cells.
Thus, the ability of anti-MMR antibody to inhibit virus capture
and subsequent virus transmission to T cells further supports theidea that the interaction of HIV-1 with MDM is predominantly
MMR-mediated.
These findings were confirmed by microscopic evaluation
(Figs. 4C–F). In fact, we could show that the anti-MMR anti-
body (panel F) completely prevented syncytia formation in HIV-
1-exposed MDM cell cultures cocultured with C8166 (panel C).
In contrast, the presence of anti-CD4 (panel D) or anti-DC-SIGN
(panel E) antibodies did not prevent this cytopathic effect.
Inhibitory effect of mannan on the ability of MDM to capture
HIV-1
To further confirm the role of MMR in HIV capture byMDM
we added mannan (at 2.5 mg/ml) to the MDM cultures. Two
different procedures were used: (i) the mannan was added to
MDM for 15 min at 37 °C and then the virus was added
(67×103 pg/100 μl for 2 h at 37 °C), and (ii) the mannan was
mixed with the virus (67×103 pg for 15 min at 37 °C) and then
the mannan/virus mixture was exposed toMDM for 2 h at 37 °C.
Then the cells were thoroughly washed to remove free unbound
virus and mannan. As evident from Fig. 5, mannan was able to
partially prevent the HIV-1 NL4.3 capture by MDM under both
experimental conditions.
Discussion
Studies have shown that MDM and DC are among the very
first cells in the subepithelial vaginal mucosa to be bound by, or
infected with, HIV during heterosexual transmission (Greenhead
et al., 2000; Hu et al., 2000;Miller and Shattock, 2003). Given the
fact thatMDMexpress high levels ofMMR (Linehan et al., 1999)
and the abundance of exposed mannose residues on the HIV
gp120 envelope (Mizuochi et al., 1988; Zhu et al., 2000), studies
on the interactions between HIV and this receptor could offer
insights into some of the first steps of infection followingmucosal
viral exposure. We found that a variety of different HIV-1 strains
could be efficiently captured by MDM. The efficiency of virus
capture depended on the nature of the virus isolate. It should be
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the R5HIV-1 strains, as shown in Fig. 2 inwhich HIV-1BaL (R5)
is captured at a ∼10-fold lesser efficiency as for example HIV-1
NL4.3 (X4). However, in contrast with R5 virus, a significant
productive infection of MDM with X4 strains is never observed
(as revealed by comparative p24 analysis at 14 days after HIV-1
R5 orX4 infection). Thus, virus capture byMDMand subsequent
productive virus infection of the MDM are two separate events.
MDM cultures exposed to X4 HIV-1 and cocultivated with
uninfected C8166 for as few as 3–4 days showed a markedly
increased HIV-1 p24 production, in contrast with MDM exposed
to X4 HIV-1 but not cocultivated with C8166 cells. MDM could
indeed efficiently transmit captured HIV-1 particles to unin-
fected T-lymphocytes, resulting in a productive infection of the
T-lymphocytes and subsequent abundant syncytia formation.
This pronounced virus transmission efficiency by MDM proved
still inferior to the rate of virus transmission from HIV-1-captured
Raji/DC-SIGN cells to T-lymphocytes. Indeed, abundant virus
production and syncytia formation in C8166 cell cocultures and
concomitant HIV-1 p24 production occur at least 1 day earlier in
cocultures of HIV-capturedRaji/DC-SIGNwith C8166 cells when
compared with cocultures of virus-captured MDM with C8166
cells (Balzarini et al., 2007a and data not shown). Thus, although
the efficiency of capturing of the different HIV-1 strains byMDM
closely paralleled capture efficiency by DC-SIGN (Fig. 2), our
observations suggest that virus transmission of captured virus
particles by DC-SIGN-expressing dendritic cells may be more
efficient than virus transmission byMMR-expressingmacrophage
cells. Since we could also demonstrate that the MDM cultures
express significant levels of MMR but not DC-SIGN, we may
conclude that HIV capture byMDM and subsequent transmission
to T-lymphocytes might be most likely directed by MMR. The
inhibitory effect of the anti-MMR antibody but not the anti-DC-
SIGN and anti-CD4 antibody against HIV-1 capture by MDM,
further support the instrumental role ofMMR in virus capture (and
subsequent transmission) of HIV by MDM.
If CBAs such as the mannose-specific plant lectins HHA,
GNA, NPA, CA, the mannose-specific non-peptidic antibiotic
PRM-A, or the GlcNAc-specific UDA are present in the envi-
ronment of the virus, they may bind to the glycans of gp120,
preventing efficient capture of the virus by the MMR of MDM.
The observation that UDA is effective in inhibiting HIV capture
by MDM, at a lesser efficiency than the mannose-specific CBA,
can be explained by the reported lower affinity of MMR for
GlcNAc compared with mannose (Zamze et al., 2002). The lower
efficiency of the non-peptidic PRM-A on MMR-directed HIV-1
capture than the lectins might be explained by a lower affinity of
PRM-A to gp120 than the lectins. This has indeed recently been
demonstrated for HHA versus PRM-A (Balzarini et al., 2007b).
We believe that our findings are relevant to be taken into
account in the choice and development of (novel) candidate
microbicide drugs. Indeed, during sexual intercourse, the very
first sites of interaction of HIV in the infected individual are
thought to be predominantly immature DCs that are present in the
vaginal mucosa, but also MDM. The C-type mannose-specific
lectins DC-SIGN and MMR may function as efficient receptors
responsible for the capture of HIV through interaction withthe glycans of HIV gp120. The findings that CBAs efficiently
prevent the virus capture and subsequent transmission to CD4+
T-lymphocytes by MDM (and DC-SIGN)-expressing cells and
that the CBA not only prevent capture of X4 HIV-1 strains by
MDMbut also prevent productive R5HIV-1 replication inMDM,
may make CBAs instrumental in preventing the establishment of
new infections through sexual intercourse. However, recently, it
was reported that langerin, a C-type lectin that is present in
epithelial Langerhans cells (LC), prevents HIV-1 transmission by
internalization of captured HIV particles and subsequent
intracellular degradation (de Witte et al., 2007). Although such
as mechanism may be efficient for a first-line inactivation of HIV,
CBA-exposedHIV strains may perhaps decrease the efficiency of
LC to eliminate HIV, but at the same time may also compromise
the ability of the virus to be efficiently transmitted by DC and
MDM as well. In vivo models (i.e. SIV-infected monkeys) may
reveal the relative importance of the effect of CBAs on the virus
capture/transmission/inactivation by the different cell types.
Materials and methods
Test compounds
The mannose-specific plant lectins from Hippeastrum hybrid
(HHA), Galanthus nivalis (GNA), Narcissus pseudonarcissus
(NPA), Cymbidium agglutinin (CA) and the GlcNAc-specific
plant lectin from Urtica dioica (UDA) were derived and purified
from these plants, as described before (Van Damme et al., 1987,
1988, 1992). Pradimicin A (PRM-A) (MW 838) was isolated and
purified from the fermentation broth ofActinomadura hibisca and
kindly provided byDr. Y. Igarashi. Cyanovirin (CV-N)was kindly
provided by Dr. JB McMahon (National Institutes of Health,
Bethesda, MD) and Dr. A Bolmstedt (Göteborg, Sweden).
Mannan (from Saccharomyces cerevisiae) was fromSigma (MO).
Cells
Human T-lymphocytic C8166 cells were obtained from the
American Type Culture Collection (Manassas, VA). Exponential-
ly growing B-lymphoblast DC-SIGN-expressing Raji/DC-SIGN
cells (Raji/DC-SIGN) were constructed by Geijtenbeek et al.
(2000) and kindly provided by Dr. L Burleigh (Institut Pasteur,
Paris, France). All cell lines mentioned were cultivated in RPMI-
1640 medium supplemented with 10% fetal bovine serum (FBS)
(BioWittaker Europe, Verviers, Belgium), 2 mM L-glutamine and
0.075 M NaHCO3.
MDM were obtained from the blood of healthy seronegative
donors by separation over a Ficoll-Hypaque gradient as pre-
viously described (Aquaro and Perno, 2005). Briefly, peripheral
bloodmononuclear cells (PBMC)were seeded in 48-well plates at
1.8×106 cells/well in 1 ml of RPMI 1640 medium containing
20% heat-inactivated endotoxin and mycoplasma-free fetal
bovine serum (Hyclone Laboratories, Inc., Logan, UT), 4 mM
L-glutamine (Life Technologies), 50 U/ml penicillin and 50 μg/ml
streptomycin (Life Technologies) (hereinafter referred to as com-
plete medium). Six days after plating and culturing the PBMC at
37 °C in a humidified atmosphere enriched with 5% CO2, non-
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warmRPMI-1640medium, leaving amonolayer of adherent cells
which were eventually incubated in complete medium. Cell cul-
tures treated under these experimental conditions have been
shown to consist of N97% MDM, as determined by cytofluori-
metric analyses (Aquaro et al., 2000).
Viruses
HIV-1 (IIIB and BaL) was provided by R. C. Gallo and M.
Popovic (at that time at the National Cancer Institute, National
Institutes of Health, Bethesda, MD). HIV-1(HE) is a clinical
isolate, derived from a Belgian AIDS patient in 1987 and later
propagated in MT-4 cells. HIV-1 NL4.3, MN, RF, were obtained
through the AIDS Research and Reference Reagent Program
(Division of AIDS, NIAID, NIH).
Antiviral effect of CBAs against HIV-1 BaL infection of MDM
MDM, obtained from blood of seronegative donors, were pre-
treated for 30 min with several concentrations of CBAs, and
infectedwith 3000 pg/ml of HIV-1 BaL. After 2 h of infection, the
medium was removed, the cells were washed four times with
RPMI-1640, and the MDM further cultured in the presence of the
CBAs. At day 7, the supernatants were collected, and CBA-
containing fresh medium added to the new medium. At 14 days,
the supernatants were collected and tested for p24 antigen
production by p24 ELISA (Perkin Elmer, Boston, MA). Each
experiment was run in triplicate.
The geometric mean of p24 gag production of replicates in
each experiment was used to determine the effective drug
concentration where 50% and 90% of viral replication was
inhibited (representing the EC50 and EC90, respectively), by
linear regression of the log of the percent HIV-1-p24
production (compared to untreated controls) versus the log
of the drug concentration.
HIV-1-capture by Raji/DC-SIGN cells and MDM
Raji/DC-SIGN cells were suspended in cell culture medium at
6×106 cells/400 μl. 0.4-ml suspensions of Raji/DC-SIGN cells
were exposed to 0.6 ml HIV-1 for 60 min, after which 39 ml of
culture medium was added to the virus-infected cell culture. The
cells were centrifuged at 1250 rpm for 10 min, and 39.9 ml su-
pernatant carefully removed. The virus-exposed cells were then
resuspended in 39.9 ml medium. After a second centrifugation
step, 39.9 ml supernatant was again removed, and the remaining
0.1 ml cell suspension was 10-fold diluted in cell culture medium
(1 ml). Under these experimental (washing) conditions, a maxi-
mum of 8 pg HIV-1 p24 could have remained in the 1 ml su-
pernatant (or 0.4 pg in 50 μl). The Raji/DC-SIGN cell cultures
were then analysed for p24 content by a p24 ELISA (Perkin
Elmer).
MDM obtained by Ficoll-Hypaque from the blood of sero-
negative donors were exposed to 100 μl of HIV-1 for 2 h after
which 4 washes with RPMI-1640 medium (20% FBS) were
performed to remove the unbound virus. To confirm the efficientremoval of unbound virus, we collected 100 μl from the last
wash to be analyzed by p24 ELISA (Perkin Elmer). Then, the
MDM were detached from the plates and analyzed for captured
HIV-1 p24 by a HIV-1 p24 ELISA. The percentage of captured
p24 HIV-1 (pg/ml) was calculated compared with the initially
administered HIV-1 p24 (pg/ml).
Effect of short exposure of HIV-1 to the CBAs on
HIV-1-capture by MDM
HIV-1 was pre-exposed to several dilutions of the CBAs for
30 min at 37 °C. Then drug-exposed virus suspensions (HIV-1
NL4.3 67×103 pg in 100μl) were added toMDM for 2 h at 37 °C.
After the incubation period, the virus was removed and the cells
were carefully washed four times with RPMI-1640 (20%FBS), to
remove the unbound virus in the wells. To confirm the efficient
removal of unbound virus, we collected 100 μl from the last wash
to be analyzed by a p24 ELISA (Perkin Elmer). Then the cells
were detached from the wells and collected to analyze the HIV-1
p24-capture by ELISA test.
Effect of short exposure of HIV-1 to CBAs on virus
transmission from MDM to T-lymphocyte cells
Human T-lymphocyte C8166 cells (100×103 cells/well in 1ml
RPM-1640 (10% FBS)) were added to CBA-exposed HIV-1-
captured MDM (prepared as described above). We then deter-
mined the HIV-1 transmission from virus-captured MDM to
C8166 cells by analyzing the HIV-1 p24 production by ELISA
in the supernatants from the cocultures at 3 and 4 days post
cocultivation.
Flow cytometric analysis
To analyze the dendritic cell-specific ICAM-3 grabbing
nonintegrin (DC-SIGN) and macrophage mannose receptor
(MMR) expression on MDM, the cells were stained with anti-
DC-SIGN (DCN46-FITC; BD Biosciences) and anti-MMR
(CD206-PE; BD Biosciences) and the samples processed for
flow cytometric analysis as previously described (Vermeire et
al., 2003).
Effects of anti-CD4, -MMR and -DC-SIGN antibodies and
mannan on HIV-1 capture by MDM and subsequent transmission
to T lymphocytes
MDM were pre-incubated with antibodies (anti-macrophage
mannose receptor (MMR) antibody CD206, BD Pharmingen:
10 μg/ml; anti-DC-SIGN antibody, BD Pharmingen: 10 μg/ml;
anti-CD4 antibody, BD Pharmingen: 10 μg/ml) for 15 min at
37 °C. HIV NL4.3 (67×103 pg/100 μl) was then added and
incubated for 2 h at 37 °C. For the mannan administration, we
used two different procedures: (1) mannan (2.5 mg/ml) was
added to MDM for 15 min at 37 °C after which the virus
(67×103 pg/100 μl) was added for 2 h at 37 °C; and (2) mannan
(2.5 mg/ml) was mixed with virus (67×103 pg/100 μl) for
15 min at 37 °C and then added to MDM for 2 h at 37 °C. Cells
390 M. Pollicita et al. / Virology 370 (2008) 382–391were washed four times with RPMI-1640 (20% FBS) to remove
unbound virus, and the cells were detached from the wells and
collected to analyze the captured HIV-1 p24 by ELISA. For the
HIV-1 transmission experiment, MDM were further cocultured
with C8166 cells for 3 or 4 days and then supernatants were
analyzed to determine virus transmission (replication) to the
C8166 cells.
CBA toxicity
To assess the CBA toxicity in the MDM cultures, we used
three uninfected cell culture controls in which the MDM were
treated with different concentrations of CBAs and cell viability
of the MDM analysed after 14 days of culture. The analysis was
obtained by light microscopy and the trypan blue dye exclusion
method.
Statistical analysis
The experiments were carried out in triplicate, with six positive
controls (untreated virus-infected cells) for each experiment, and
the results are presented as mean values with standard deviation.
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